Q-omics provides the consensus-scored KIAA2026 profile across patient tissues and cancer cell-line models. KIAA2026 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIAA2026 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, KIAA2026 RNA expression shows 21,436 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where KIAA2026 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA2026 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA2026 survival associations across molecular data types. KIAA2026 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA2026 RNA expression–survival associations across cancer types. High KIAA2026 expression shows unfavorable associations in MESO, but favorable associations in KIRC, LGG, SKCM, GBM and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIAA2026 RNA expression.
This table summarizes KIAA2026 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KIAA2026. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA2026 shows lower tumor expression in THCA, KIRC and UCEC and higher tumor expression in CHOL, LIHC and HNSC. The THCA box plot shows higher KIAA2026 RNA expression in normal versus tumor tissue (log2 FC = −0.439, t-test p < 0.001).
This table shows molecular features associated with KIAA2026 in patient tissues and cancer cell lines. In patient samples, KIAA2026 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA2026 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
